ReviewFrontiers in cellular and infection microbiology2012
Current and novel approaches to vaccine development against tuberculosis.
Review in Frontiers in cellular and infection microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Article
- The chaperone GrpE mediates adhesion in Mycoplasma bovis and interactions with host extracellular matrix components and plasminogen.Veterinary research · 2025Article
- Particle Dynamics and Bioaerosol Viability of Aerosolized Bacillus Calmette-Guérin Vaccine Using Jet and Vibrating Mesh Clinical Nebulizers.Journal of aerosol medicine and pulmonary drug delivery · 2022Article
- Article
- GrpE Immunization Protects AgainstFrontiers in immunology · 2020Article
- A polymeric immunoglobulin-antigen fusion protein strategy for enhancing vaccine immunogenicity.Plant biotechnology journal · 2018Article
- Comparison of immunogenicity and vaccine efficacy between heat-shock proteins, HSP70 and GrpE, in the DnaK operon of Mycobacterium tuberculosis.Scientific reports · 2018Article
- Incidence of tuberculosis among school-going adolescents in South India.BMC public health · 2016Article
- NR1D1 ameliorates Mycobacterium tuberculosis clearance through regulation of autophagy.Autophagy · 2015Article
- Effects of CHO-expressed recombinant lactoferrins on mouse dendritic cell presentation and function.Innate immunity · 2015Article
- Evolution of M. bovis BCG Vaccine: Is Niacin Production Still a Valid Biomarker?Tuberculosis research and treatment · 2015Review
- Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- HspX vaccination and role in virulence in the guinea pig model of tuberculosis.Pathogens and disease · 2014Article
- Host immune responses to mycobacterial antigens and their implications for the development of a vaccine to control tuberculosis.Clinical and experimental vaccine research · 2014Review
- Interaction sites of DivIVA and RodA from Corynebacterium glutamicum.Frontiers in microbiology · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Antibiotics and vaccines are the two most successful medical countermeasures that humans have created against a number of pathogens. However a select few e.g., Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB) have evaded eradication by vaccines and therapeutic approaches. TB is a global public health problem that kills 1.4 million people per year. The past decade has seen significant progress in developing new vaccine candidates, but the most fundamental questions in understanding disease progression and protective host responses that are responsible for controlling Mtb infection still remain poorly resolved. Current TB treatment requires intense chemotherapy with several antimicrobials, while the only approved vaccine is the classical viable whole-cell based Bacille-Calmette-Guerin (BCG) that protects children from severe forms of TB, but fails to protect adults. Taken together, there is a growing need to conduct basic and applied research to develop novel vaccine strategies against TB. This review is focused on the discussion surrounding current strategies and innovations being explored to discover new protective antigens, adjuvants, and delivery systems in the hopes of creating an efficacious TB vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.